Glaukos Corp
NYSE:GKOS

  • LAST PRICE
    131.3800
  • TODAY'S CHANGE (%)
    -0.3900 (-0.2960%)
  • Bid / Lots
    118.0000/ 1
  • Ask / Lots
    126.0000/ 1
  • Open / Previous Close
    130.4000 / 131.7700
  • Day Range
    128.9600
    133.7750
  • 52 Week Range
    59.2200
    139.5050
  • Volume
    815,515

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 4 hours ago by MT Newswires
      Companies Mentioned: GKOS
      05:14 PM EST, 11/04/2024 (MT Newswires) -- Glaukos (GKOS) reported a Q3 non-GAAP loss late Monday of $0.28 per diluted share, narrowing from a $0.50 loss per share a year earlier. Analysts polled by Capital IQ expected a $0.48 loss per share. Net sa...

    • 5 hours ago by MT Newswires
      Companies Mentioned: GKOS
      04:15 PM EST, 11/04/2024 (MT Newswires) -- ...

    • 5 hours ago by MT Newswires
      Companies Mentioned: GKOS
      04:15 PM EST, 11/04/2024 (MT Newswires) -- ...

    • 6 hours ago by Dow Jones
      Companies Mentioned: GKOS
      ------------------------------------------ -------------------------------------------- GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP --------- --------------- --------- --------- --------------- ----------- Cost of sales $ 22,584 $ (5,523) (a) $ 17,061 $ 18,510 $ (5,523) (a) $ 12,987 Gross Margin 76.6% 5.8% 82.4% 76.3% 7.1% 83.4% Operating expenses: ---------------- Selling, general and administrative $ 64,000 $ (705) (b) $ 63,295 $ 54,247 $ (705) (b) $ 53,542 Loss from operations $(24,660) $ 6,228 $(18,432) $(28,010) $ 6,228 $(21,782) Net loss $(21,409) $ 6,228 (c) $(15,181) $(30,444) $ 6,228 (c) $(24,216) Basic and diluted net loss per share $ (0.39) $ 0.11 $ (0.28) $ (0.63) $ 0.13 $ (0.50) (a) Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $5.5 million. (b) Avedro acquisition-related amortization expense of customer relationship intangible assets of $0.7 million. (c) Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2024 and 2023. GLAUKOS CORPORATION GAAP to Non-GAAP Reconciliations (in thousands, except per share amounts and percentage data) (unaudited) Year-to-Date Q3 2024 Year-to-Date Q3 2023 ----------------------------------------- --------------------------------------------- GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP ---------- ------------- --------- ------------ ------------- ----------- Cost of sales $ 65,392 $ (16,569) (a) $ 48,823 $ 56,684 $ (16,569) (a) $ 40,115 Gross Margin 76.5% 5.9% 82.4% 75.6% 7.1% 82.7% Operating expenses: ---------------- Selling, general and administrative $ 192,163 $ (2,115) (b) $190,048 $161,034 $ (2,115) (b) $158,919 Loss from operations $ (93,700) $ 18,684 $(75,016) $(90,078) $ 18,684 $(71,394) Non-operating income (expense): ---------------- Charges associated with convertible senior notes $ (18,012) $ 18,012 (c) $ - $ - $ - $ - Net loss $(112,792) $ 36,696 (d) $(76,096) $(97,882) $ 18,684 (d) $(79,198) Basic and diluted net loss per share $ (2.18) $ 0.71 $ (1.47) $ (2.03) $ 0.39 $ (1.64) (a) Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $16.6 million. (b) Avedro acquisition-related amortization expense of customer relationship intangible assets of $2.1 million. (c) Expenses associated with the exchange of convertible senior notes, consisting of a non-cash inducement charge of $17.4 million and direct transaction costs of $0.6 million. (d) Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2024 and 2023. Reported Sales vs. Prior Periods (in thousands) ------------------------------------------------------------------------------------------------------------------------- Year-over-Year Percent Change Quarter-over-Quarter Percent Change ------ ------ ------ ------------------------------------- ------------------------------------- 3Q 3Q 2Q Operations Operations 2024 2023 2024 Reported (1) Currency (2) Reported (1) Currency (2) ------- ------- ------- --------- ----------- ------------- --------- ----------- ------------- International Glaucoma $24,467 $20,280 $26,131 20.6% 20.9% (0.2%) (6.4%) (8.2%) 1.8% Total Net Sales $96,670 $78,048 $95,690 23.9% 23.9% (0.0%) 1.0% 0.5% 0.5% ---------------- ------ ------ ------ --------- ----------- ------------- --------- ----------- ------------- (1) Operational growth excludes the effect of translational currency (2) Calculated by converting the current period numbers using the prior period's average foreign exchange rates

    • 6 hours ago by Dow Jones
      Companies Mentioned: GKOS
      ------------------------------------------ -------------------------------------------- GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP --------- --------------- --------- --------- --------------- ----------- Cost of sales $ 22,584 $ (5,523) (a) $ 17,061 $ 18,510 $ (5,523) (a) $ 12,987 Gross Margin 76.6% 5.8% 82.4% 76.3% 7.1% 83.4% Operating expenses: ---------------- Selling, general and administrative $ 64,000 $ (705) (b) $ 63,295 $ 54,247 $ (705) (b) $ 53,542 Loss from operations $(24,660) $ 6,228 $(18,432) $(28,010) $ 6,228 $(21,782) Net loss $(21,409) $ 6,228 (c) $(15,181) $(30,444) $ 6,228 (c) $(24,216) Basic and diluted net loss per share $ (0.39) $ 0.11 $ (0.28) $ (0.63) $ 0.13 $ (0.50) (a) Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $5.5 million. (b) Avedro acquisition-related amortization expense of customer relationship intangible assets of $0.7 million. (c) Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2024 and 2023. GLAUKOS CORPORATION GAAP to Non-GAAP Reconciliations (in thousands, except per share amounts and percentage data) (unaudited) Year-to-Date Q3 2024 Year-to-Date Q3 2023 ----------------------------------------- --------------------------------------------- GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP ---------- ------------- --------- ------------ ------------- ----------- Cost of sales $ 65,392 $ (16,569) (a) $ 48,823 $ 56,684 $ (16,569) (a) $ 40,115 Gross Margin 76.5% 5.9% 82.4% 75.6% 7.1% 82.7% Operating expenses: ---------------- Selling, general and administrative $ 192,163 $ (2,115) (b) $190,048 $161,034 $ (2,115) (b) $158,919 Loss from operations $ (93,700) $ 18,684 $(75,016) $(90,078) $ 18,684 $(71,394) Non-operating income (expense): ---------------- Charges associated with convertible senior notes $ (18,012) $ 18,012 (c) $ - $ - $ - $ - Net loss $(112,792) $ 36,696 (d) $(76,096) $(97,882) $ 18,684 (d) $(79,198) Basic and diluted net loss per share $ (2.18) $ 0.71 $ (1.47) $ (2.03) $ 0.39 $ (1.64) (a) Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $16.6 million. (b) Avedro acquisition-related amortization expense of customer relationship intangible assets of $2.1 million. (c) Expenses associated with the exchange of convertible senior notes, consisting of a non-cash inducement charge of $17.4 million and direct transaction costs of $0.6 million. (d) Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2024 and 2023. Reported Sales vs. Prior Periods (in thousands) ------------------------------------------------------------------------------------------------------------------------- Year-over-Year Percent Change Quarter-over-Quarter Percent Change ------ ------ ------ ------------------------------------- ------------------------------------- 3Q 3Q 2Q Operations Operations 2024 2023 2024 Reported (1) Currency (2) Reported (1) Currency (2) ------- ------- ------- --------- ----------- ------------- --------- ----------- ------------- International Glaucoma $24,467 $20,280 $26,131 20.6% 20.9% (0.2%) (6.4%) (8.2%) 1.8% Total Net Sales $96,670 $78,048 $95,690 23.9% 23.9% (0.0%) 1.0% 0.5% 0.5% ---------------- ------ ------ ------ --------- ----------- ------------- --------- ----------- ------------- (1) Operational growth excludes the effect of translational currency (2) Calculated by converting the current period numbers using the prior period's average foreign exchange rates

Peers Headlines